These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 28025766)

  • 21. Cardioversion under the guidance of transesophageal echochardiograhy in persistent atrial fibrillation: results with low molecular weight heparin.
    Akdeniz B; Türker S; Oztürk V; Badak O; Okan T; Aslan O; Kozan O; Kirimli O; Aytekin D; Bariş N; Güneri S
    Int J Cardiol; 2005 Jan; 98(1):49-55. PubMed ID: 15676166
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Short-term anticoagulation after acute cardioversion of early-onset atrial fibrillation.
    Saglietto A; De Ferrari GM; Gaita F; Anselmino M
    Eur J Clin Invest; 2020 Nov; 50(11):e13316. PubMed ID: 32535904
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low stroke risk after elective cardioversion of atrial fibrillation: an analysis of the Flec-SL trial.
    Apostolakis S; Haeusler KG; Oeff M; Treszl A; Andresen D; Borggrefe M; Lip GY; Meinertz T; Parade U; Samol A; Steinbeck G; Wegscheider K; Breithardt G; Kirchhof P
    Int J Cardiol; 2013 Oct; 168(4):3977-81. PubMed ID: 23871349
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardiovascular Events of Electrical Cardioversion Under Optimal Anticoagulation in Atrial Fibrillation: The Multicenter Analysis.
    Shin DG; Cho I; Hartaigh Bó; Mun HS; Lee HY; Hwang ES; Park JK; Uhm JS; Pak HN; Lee MH; Joung B
    Yonsei Med J; 2015 Nov; 56(6):1552-8. PubMed ID: 26446636
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).
    Singer DE; Albers GW; Dalen JE; Fang MC; Go AS; Halperin JL; Lip GYH; Manning WJ
    Chest; 2008 Jun; 133(6 Suppl):546S-592S. PubMed ID: 18574273
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intensity of anticoagulation and risk of thromboembolism after elective cardioversion of atrial fibrillation.
    Hellman T; Kiviniemi T; Nuotio I; Vasankari T; Hartikainen J; Lip GYH; Airaksinen KEJ
    Thromb Res; 2017 Aug; 156():163-167. PubMed ID: 28662483
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Usefulness of transoesophageal echocardiography before cardioversion in patients with atrial fibrillation and different anticoagulant regimens.
    Maltagliati A; Galli CA; Tamborini G; Calligaris A; Doria E; Salehi R; Pepi M
    Heart; 2006 Jul; 92(7):933-8. PubMed ID: 16284221
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sex-related differences in presentation, treatment, and outcome of patients with atrial fibrillation in Europe: a report from the Euro Observational Research Programme Pilot survey on Atrial Fibrillation.
    Lip GY; Laroche C; Boriani G; Cimaglia P; Dan GA; Santini M; Kalarus Z; Rasmussen LH; Popescu MI; Tica O; Hellum CF; Mortensen B; Tavazzi L; Maggioni AP
    Europace; 2015 Jan; 17(1):24-31. PubMed ID: 24957921
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anticoagulation during cardioversion in patients with atrial fibrillation: current clinical practice.
    Stellbrink C; Schimpf T
    Am J Cardiovasc Drugs; 2005; 5(3):155-62. PubMed ID: 15901203
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Transoesophageal echocardiography-guided cardioversion of atrial fibrillation or flutter. Selection of a low-risk group for immediate cardioversion.
    Roijer A; Eskilsson J; Olsson B
    Eur Heart J; 2000 May; 21(10):837-47. PubMed ID: 10781356
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of CHADS2 score in evaluation of thromboembolic risk and mortality in patients with atrial fibrillation undergoing direct current cardioversion (from the ACUTE Trial Substudy).
    Yarmohammadi H; Varr BC; Puwanant S; Lieber E; Williams SJ; Klostermann T; Jasper SE; Whitman C; Klein AL
    Am J Cardiol; 2012 Jul; 110(2):222-6. PubMed ID: 22503581
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of transesophageal echocardiography-guided cardioversion of patients with atrial fibrillation at 6 months: a randomized controlled trial.
    Klein AL; Grimm RA; Jasper SE; Murray RD; Apperson-Hansen C; Lieber EA; Black IW; Davidoff R; Erbel R; Halperin JL; Orsinelli DA; Porter TR; Stoddard MF;
    Am Heart J; 2006 Feb; 151(2):380-9. PubMed ID: 16442904
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Advances in anticoagulation management of patients undergoing cardioversion of nonvalvular atrial fibrillation.
    Benetos G; Bonou M; Toutouzas K; Diamantopoulos P; Viniou N; Barbetseas J
    Hamostaseologie; 2017 Oct; 37(4):277-285. PubMed ID: 28289746
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Changes in oral anticoagulation for elective cardioversion: results from a European cardioversion registry.
    Papp J; Zima E; Bover R; Karaliute R; Rossi A; Szymanski C; Troccoli R; Schneider J; Fagerland MW; Camm AJ; Atar D
    Eur Heart J Cardiovasc Pharmacother; 2017 Jul; 3(3):147-150. PubMed ID: 28329309
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thromboembolic events occur despite sinus rhythm maintenance in patients treated for atrial fibrillation: The Canadian Trial of Atrial Fibrillation experience.
    Thibault B; Talajic M; Dubuc M; Guerra P; Gagné P; Roy D; Connolly S;
    Can J Cardiol; 2004 Feb; 20(2):195-9. PubMed ID: 15010743
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anticoagulation Control in Warfarin-Treated Patients Undergoing Cardioversion of Atrial Fibrillation (from the Edoxaban Versus Enoxaparin-Warfarin in Patients Undergoing Cardioversion of Atrial Fibrillation Trial).
    Lip GYH; Al-Saady N; Jin J; Sun M; Melino M; Winters SM; Zamoryakhin D; Goette A
    Am J Cardiol; 2017 Sep; 120(5):792-796. PubMed ID: 28709650
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A prospective evaluation of edoxaban compared to warfarin in subjects undergoing cardioversion of atrial fibrillation: The EdoxabaN vs. warfarin in subjectS UndeRgoing cardiovErsion of Atrial Fibrillation (ENSURE-AF) study.
    Lip GY; Merino J; Ezekowitz M; Ellenbogen K; Zamoryakhin D; Lanz H; Jin J; Al-Saadi N; Mercuri M; Goette A
    Am Heart J; 2015 May; 169(5):597-604.e5. PubMed ID: 25965706
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vitamin K Antagonists Versus Novel Oral Anticoagulants for Elective Electrical Cardioversion of Atrial Fibrillation.
    Ţînţ D; Petriş AO; Pop I; Melnic R; Ignat AM; Rogozea LM
    Am J Ther; 2017; 24(5):e553-e558. PubMed ID: 28661896
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial Fibrillation.
    Renda G; Zimarino M; Ricci F; Piccini JP; Ezekowitz MD; Patel MR; Cappato R; Giugliano RP; De Caterina R
    Am J Med; 2016 Oct; 129(10):1117-1123.e2. PubMed ID: 27262782
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevention of embolic events after cardioversion of atrial fibrillation. Current and evolving strategies.
    Kinch JW; Davidoff R
    Arch Intern Med; 1995 Jul; 155(13):1353-60. PubMed ID: 7794083
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.